Table 1.
Kinase fusions identified in Ph-like ALL
| Kinase gene | TKI | Fusion partners identified to date, n | 5′ Fusion partners |
|---|---|---|---|
| ABL1 | Imatinib/dasatinib | 13 | CENPC, ETV6, FOXP1, LSM14A, NUP153, NUP214, RANBP2, RCSD1, SFPQ, SNX1, SNX2, SPTNA1, ZMIZ1 |
| ABL2 | Imatinib/dasatinib | 3 | PAG1, RCSD1, ZC3HAV1 |
| CSF1R | Imatinib/dasatinib | 3 | MEF2D, SSBP2, TBL1XR1 |
| PDGFRA | Imatinib/dasatinib | 1 | FIP1L1 |
| PDGFRB | Imatinib/dasatinib | 8 | ATF7IP, EBF1, ETV6, SNX29, SSBP2, TNIP1, ZEB2, ZMYND8 |
| LYN | Imatinib/dasatinib | 2 | GATAD2A, NCOR1 |
| CRLF2 | JAK2 inhibitor | 3 | CSF2RA, IGH, P2RY8 |
| JAK2 | JAK2 inhibitor | 21 | ATF7IP, BCR, EBF1, ETV6, GOLGA5, HMBOX1, OFD1, PAX5, PCM1, PPFIBP1, RFX3, SMU1, SNX29, SSBP2, STRN3, TERF2, TPR, USP25, ZBTB46, ZNF274, ZNF340 |
| EPOR | JAK2 inhibitor | 4 | IGH, IGK, LAIR1, THADA |
| TSLP | JAK2 inhibitor | 1 | IQGAP2 |
| TYK2 | TYK2 inhibitor | 3 | MYB, SMARCA4, ZNF340 |
| IL2RB | JAK1/JAK3 inhibitor | 1 | MYH9 |
| NTRK3 | TRK inhibitor | 1 | ETV6 |
| PTK2B | FAK inhibitor | 3 | KDM6A, STAG2, TMEM2 |
| FGFR1 | Ponatinib | 1 | BCR |
| FLT3 | FLT3 inhibitor | 1 | ZMYM2 |
| DGKH | 1 | ZFAND3 | |
| BLNK | 1 | DNTT | |
| CBL | 1 | KANK1 |